You are here

  • Home
  • Archive
  • Volume 7, Issue 2
  • Clopidogrel plus aspirin was effective but increased bleeding in acute coronary syndromes without ST-segment elevation

Article Text

Article menu
Download PDFPDF
Therapeutics
Clopidogrel plus aspirin was effective but increased bleeding in acute coronary syndromes without ST-segment elevation

https://doi.org/10.1136/ebm.7.2.43

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2001) N Engl J Med 345, 494. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators.. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.. Aug 16;. :. –502.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: What is the efficacy and safety of early and long term use of clopidogrel plus aspirin and aspirin alone in patients with acute coronary syndromes without ST-segment elevation?

    Design

    Randomised (allocation concealed*), blinded {patients, healthcare providers, data collectors, outcome assessors, monitoring committee, statisticians, and manuscript writers}†,* placebo controlled trial with 12 months of follow up (Clopidogrel in Unstable Angina to Prevent Recurrent Events [CURE] Trial).

    Setting

    482 centres in 28 countries.

    Patients

    12 562 patients (mean age 64 y, 62% men) who were admitted to hospital within 24 hours of symptom onset, had either electrocardiographic changes or elevated concentrations of cardiac enzymes, and did not have ST-segment elevation. Exclusion criteria were contraindications to antithrombotic or antiplatelet treatment, high risk …

    View Full Text

    Footnotes

    • ↵* See glossary.

    • ↵† Information provided by author.

    • Sources of funding: Sanofi-Synthelabo and Bristol-Myers Squibb.

    • For correspondence: Dr S Yusuf, Hamilton General Hospital, Hamilton, Ontario, Canada. yusuf{at}mcmaster.ca.